College of Pharmaceutical Sciences, State Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, Hangzhou 310058, China ...

Boston, Massachusetts-based Odyssey Therapeutics, Inc. was founded to develop various inhibitor drugs for autoimmune ... 2021 and was previously founder of IFM Therapeutics and Scorpion Therapeutics.

The pipeline is led by a RIPK2 inhibitor that ... prowess and acquiring IFM Discovery for MDA5 and NLRP1 discovery programs. IFM was a subsidiary of IFM Therapeutics, a biotech founded by Odyssey ...

It is administered through oral route in the form of tablet. It acts by targeting connexin 43 (Cx43) and NLRP3. It was also under development for the treatment of diabetic retinopathy (DR). Inflammx ...

The rise in the Zydus Life share price came after the company announced that it has received approval from United States Food and Drug Administration (USFDA) to conduct Phase II(b) clinical trial for ...

Navenibart is under clinical development by Astria Therapeutics and currently in Phase II for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency). According to GlobalData, Phase II ...

IFM Investors and HESTA, by way of its mandate with the former, will take a 49% stake in Splend Group, a provider of subscription electric vehicles. IFM Investors has made the investment via its ...

NEWTON, Mass.--(BUSINESS WIRE)--Inflammasome Therapeutics (https://www.inflam.com/), a clinical-stage biotech company developing novel, first-in-class dual ...

TAMPA, Fla., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Inhibitor Therapeutics, Inc. ("Inhibitor") (OTCQB: INTI) today provided an update on development efforts for its itraconazole formulation for the ...

SAN DIEGO - Ventyx Biosciences, Inc. (NASDAQ:VTYX), a biopharmaceutical company trading near its 52-week low of $1.67, has commenced Phase 2 trials for its NLRP3 inhibitor portfolio, targeting various ...

including those in which IL-1 antagonism has already been validated as a therapeutic approach.” Pipeline Updates and Anticipated Milestones NLRP3 Inhibitor Portfolio: Ventyx is advancing a portfolio ...